

References

I-246

1. Tivdak (tisotumab vedotin-tftv), injection, for intravenous use [package insert]. Seagen, Inc. Bothell, WA. 2019. Revised 09/2021.
2. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Tisotumab vedotin-tftv.
3. Micromedex DrugDex Compendium®. 2022. Tisotumab vedotin-tftv.
4. National Comprehensive Cancer Network (NCCN). Tisotumab vedotin-tftv. NCCN Drugs and Biologics Compendium®. 2022.
5. Tisotumab vedotin-tftv In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated October 18, 2021.
6. De Bono J, Concin N, Hong D, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours: a first-in-human, multicentre, phase 1-2 trial. *Lancet Oncol*. 2019;20(3):383-93.
7. Coleman R, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*. 2021;22(5):609-19.
8. Hong D, Concin N, Vergote I, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. *Clin Cancer Res*. 2020;26(6):1220-8.